Agent for treatment of liver diseases containing pyrazolopyrimidinone derivative
    10.
    发明授权
    Agent for treatment of liver diseases containing pyrazolopyrimidinone derivative 有权
    用于治疗含有吡唑嘧啶酮衍生物的肝病的药剂

    公开(公告)号:US08796286B2

    公开(公告)日:2014-08-05

    申请号:US11916752

    申请日:2005-10-21

    CPC分类号: A61K31/519 C07D487/04

    摘要: The present invention relates to the pharmaceutical composition for prevention and treatment of liver diseases containing pyrazolopyrimidine derivative as an active ingredient. According to the present invention, pyrazolopyrimidine derivative has an excellent effect on inhibiting collagen synthesis in hepatic stellate cells and acts directly on the portal vein. Particularly, it may increase the diameter and the amount of blood flow of the portal vein, and finally decrease the pressure thereof. Therefore, pyrazolopyrimidine derivative can be used advantageously for prevention and treatment of hepatic fibrosis, liver cirrhosis caused by hepatic fibrosis, portal hypertension and various complications caused by portal hypertension. In addition, pyrazolopyrimidine derivative according to the present invention can reduce dosing frequency because of its long half-life, and therefore, has an advantage to improve the drug compliance of patients suffering from chronical liver diseases.

    摘要翻译: 本发明涉及用于预防和治疗含有吡唑并嘧啶衍生物作为活性成分的肝病的药物组合物。 根据本发明,吡唑并嘧啶衍生物对抑制肝星状细胞中的胶原合成具有优异的作用,直接作用于门静脉。 特别地,可能增加门静脉的直径和血流量,最终降低其压力。 因此,吡唑并嘧啶衍生物可有利地用于预防和治疗肝纤维化,肝纤维化引起的肝硬化,门静脉高压以及门静脉高压引起的各种并发症。 此外,根据本发明的吡唑并嘧啶衍生物由于其半衰期长而能降低给药频率,因此具有改善患有慢性肝病的患者的药物依从性的优点。